Clinical Trial Update: An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) [Phase 4]

View source ↗

Summary

This Phase 4, open-label study evaluated once-daily esomeprazole 40 mg in patients with GERD. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Nexium (esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: GERD | Phase 4 | Status: COMPLETED